-
公开(公告)号:US10508108B2
公开(公告)日:2019-12-17
申请号:US15532552
申请日:2015-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor: Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Dawn M. Hoffman , Chunhui Huang , Solomon D. Kattar , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Wanying Sun , Feroze Ujjainwalla , Zhicai Wu , Yang Yu , Craig R. Gibeau
IPC: C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号:US20190092833A1
公开(公告)日:2019-03-28
申请号:US16199774
申请日:2018-11-26
Applicant: Merck Sharp & Dohme Corp.
Inventor: Songnian Lin , Lin Yan , Pei Huo , Dmitri Pissarnitski , Danqing Feng , Ravi Nargund , Yuping Zhu , Ahmet Kekec , Christina B. Madsen-Duggan , Zhi-Cai Shi , Zhicai Wu , Yingjun Mu
Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
-
公开(公告)号:US09868733B2
公开(公告)日:2018-01-16
申请号:US14419825
申请日:2013-08-19
Applicant: Merck Sharp & Dohme Corp.
Inventor: James M. Apgar , Tesfaye Biftu , Ping Chen , Danqing Feng , Jacqueline D. Hicks , Ahmet Kekec , Kenneth J. Leavitt , Bing Li , Iyassu Sebhat , Xiaoxia Qian , Lan Wei , Robert R. Wilkening , Zhicai Wu , Ashok Arasappan
IPC: C07D471/04 , C07D519/00 , A61K31/366 , A61K31/397 , A61K31/4985 , A61K31/19 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/5377 , C07C53/18
CPC classification number: C07D471/04 , A61K31/19 , A61K31/366 , A61K31/397 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5377 , C07C53/18 , C07D519/00 , A61K2300/00
Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
-
公开(公告)号:US20170369507A1
公开(公告)日:2017-12-28
申请号:US15532549
申请日:2015-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor: Fischer Christian , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , Michael J. Ellis , Sara Esposite , Qingmei Hong , Chunhui Huang , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Ryan D. Otte , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Patrick Pengcheng Shao , David L. Sloman , Feroze Ujjainwalla , Catherine White , Zhicai Wu , Yang Yu , Kake Zhao , Craig R. Gibeau
IPC: C07D498/08 , C07D471/04 , C07D498/10 , C07D471/08 , A01N43/00
CPC classification number: C07D498/08 , A01N43/00 , A61K31/551 , C07D471/04 , C07D471/08 , C07D471/14 , C07D498/04 , C07D498/10
Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号:US20170362220A1
公开(公告)日:2017-12-21
申请号:US15532552
申请日:2015-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor: Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , Michael J. Ellis , Sara Esposite , Dawn M. Hoffman , Chunhui Huang , Solomon D. Kattar , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Patrick Pengcheng Shao , David L. Sloman , Wanying Sun , Feroze Ujjainwalla , Zhicai Wu , Yang Yu , Craig R. Gibeau
IPC: C07D471/04 , C07D519/00 , C07D471/14
CPC classification number: C07D471/04 , C07D471/14 , C07D519/00
Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号:US09469608B2
公开(公告)日:2016-10-18
申请号:US14443470
申请日:2013-11-15
Applicant: Merck Sharp & Dohme Corp.
Inventor: Harry Chobanian , Tesfaye Biftu , Barbara Pio , Zhicai Wu
IPC: C07D207/16 , C07D207/34 , C07D401/14 , C07D401/06 , C07D405/06 , C07D409/06 , C07D403/06 , C07D417/06
CPC classification number: C07D207/16 , C07D207/34 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D417/06
Abstract: Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; R is a heterocycle, —(CR8R9)1-2NH2, or —(CR8R9)1-2OH, wherein R8and R9, each time in which they occur, are independently H, C1-6alkyl, —CH2F, —CHF2, CF3or —CH2OH; W is a) —CHR1R2, where R1is —C(CH3)3, and R2is —(CH2)1-2OH, b) a 5- or 6-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N and O, wherein substituted heterocycle is substituted with R3, c) a 9- or 10-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N, O and S, wherein substituted heterocycle is mono-substituted with R3, or disubstituted with R3and R4, or d) a 3-, 4-, or 5-membered carbocyclic ring which is unsubstituted, mono-substituted with R3, di-substituted with R3and R4, or tri-substituted with R3, R4and R5; R3is —CF3, —COOH, —COOR7, —C(O)R6, —CH(OH)R6, —CH2R6, R6, ═O, halogen, R7, —OH, —NH2, or —NHSO2R7; and R10is H or C1-6alkyl.
-
公开(公告)号:US09403807B2
公开(公告)日:2016-08-02
申请号:US14557980
申请日:2014-12-02
Applicant: Merck Sharp & Dohme Corp.
Inventor: Alejandro Crespo , Ping Lan , Rudrajit Mal , Anthony Ogawa , Hong Shen , Peter J. Sinclair , Zhongxiang Sun , Ellen K. Vande Bunte , Zhicai Wu , Kun Liu , Robert J. DeVita , Dong-Ming Shen , Min Shu , John Qiang Tan , Changhe Qi , Yuguang Wang , Richard Beresis
IPC: C07D413/06 , C07D231/56 , A61K31/404 , A61K31/416 , C07D403/06 , C07D209/08 , C07D209/10 , A61K31/405 , A61K31/4196 , A61K31/722 , A61K31/4245 , A61K45/06 , C07D403/04 , C07D405/06 , A61K31/4045 , A61K31/422
CPC classification number: C07D413/06 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/416 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K45/06 , C07D209/08 , C07D209/10 , C07D231/56 , C07D403/04 , C07D403/06 , C07D405/06
Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
Abstract translation: 本发明涉及可用于治疗醛固酮介导的疾病的式I化合物及其药学上可接受的盐。 本发明还涉及制备式I化合物的方法,其用于治疗和预防上述疾病和用于制备用于此目的的药物,以及包含式I化合物的药物组合物。
-
公开(公告)号:US20150284376A1
公开(公告)日:2015-10-08
申请号:US14557980
申请日:2014-12-02
Applicant: Merck Sharp & Dohme Corp.
Inventor: Alejandro Crespo , Ping Lan , Rudrajit Mal , Anthony Ogawa , Hong Shen , Peter J. Sinclair , Zhongxiang Sun , Ellen K. Vande Bunte , Zhicai Wu , Kun Liu , Robert J. DeVita , Dong-Ming Shen , Min Shu , John Qiang Tan , Changhe Qi , Yuguang Wang , Richard Beresis
IPC: C07D413/06 , A61K31/405 , C07D231/56 , A61K31/416 , A61K31/4045 , A61K45/06 , C07D403/06 , A61K31/4196 , A61K31/422 , C07D403/04 , A61K31/404 , C07D405/06 , C07D209/08 , A61K31/4245
CPC classification number: C07D413/06 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/416 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K45/06 , C07D209/08 , C07D209/10 , C07D231/56 , C07D403/04 , C07D403/06 , C07D405/06
Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
Abstract translation: 本发明涉及可用于治疗醛固酮介导的疾病的式I化合物及其药学上可接受的盐。 本发明还涉及制备式I化合物的方法,其用于治疗和预防上述疾病和用于制备用于此目的的药物,以及包含式I化合物的药物组合物。
-
公开(公告)号:US20150166490A1
公开(公告)日:2015-06-18
申请号:US14351006
申请日:2012-10-08
Applicant: MERCK SHARP & DOHME CORP.
Inventor: Hong Shen , Jason M. Cox , Christine Yang , Zhicai Wu
IPC: C07D263/44 , C07D413/12 , A61K31/422 , C07D413/06 , A61K31/4725 , A61K31/421 , A61K31/4439
CPC classification number: C07D263/44 , A61K31/421 , A61K31/422 , A61K31/4439 , A61K31/4725 , C07D401/06 , C07D413/06 , C07D413/12
Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐,其可用于治疗醛固酮介导的疾病。 本发明还涉及制备式I化合物的方法,可用于治疗上述疾病和用于制备用于此目的的药物以及包含式I化合物的药物组合物。
-
公开(公告)号:US20190352294A1
公开(公告)日:2019-11-21
申请号:US16461849
申请日:2017-11-13
Applicant: Ashwin RAO , Brian Alexander MCKITTRICK , Matthew LOMBARDO , Jacqueline D. HICKS , Amy Bittner MCCRACKEN , Hong Dong CHU , Sung-Sau SO , Peter ORTH , Zhicai WU , Ping LAN , John S. DEBENHAM , Brent R. WHITEHEAD , Jerry A. TAYLOR , Zhongxiang SUN , Revathi Reddy KATIPALLY , Jonathan E. GABLE , Markus K. DAHLGREN , Sathesh P. BHAT , Merck Sharp & Dohme Corp.
Inventor: Ashwin U. Rao , Brian Alexander McKittrick , Matthew Lombardo , Jacqueline D. Hicks , Amy Bittner McCracken , Hong Dong Chu , Sung-Sau So , Peter Orth , Zhicai Wu , Ping Lan , John S. Debenham , Brent R. Whitehead , Jerry A. Taylor , Zhongxiang Sun , Revathi Reddy Katipally , Jonathan E. Gable , Markus K. Dahlgren , Sathesh P. Bhat
IPC: C07D413/14 , C07D495/04 , A61P7/02
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
-
-
-
-
-
-
-
-
-